StocktoriaenGene Therapeutics Inc. ENGNW
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-0.92
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Operating income | -$123.2M | -$62.3M | -$26.1M | -$19.4M |
| Net income | -$117.3M | -$55.1M | -$99.9M | -$24.5M |
| Operating cash flow | -$99.2M | -$48.3M | -$24.7M | -$17.6M |
| Free cash flow | -$100.7M | -$49.2M | -$25.1M | -$17.7M |
| Total assets | $221.5M | $311.2M | $87.0M | $23.9M |
| Total liabilities | $53.8M | $38.6M | $14.5M | $47.4M |
| Shareholders' equity | $167.7M | $272.6M | $72.5M | -$76.6M |
| Ratios | ||||
| Return on assets | -53.0% | -17.7% | -114.9% | -102.3% |
| Return on equity | -69.9% | -20.2% | -137.8% | 31.9% |
| Current ratio | 6.30 | 16.87 | 16.25 | 4.42 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.92 (distress)
- Working capital / assets 0.765
- Retained earnings / assets -1.68
- EBIT / assets -0.556
- Equity / liabilities 3.12
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001980845 · as of 2025-10-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.